Related Experiment Video
Updated: Jan 8, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Addressing the disease burden of systemic lupus erythematosus
Yoshiya Tanaka1, Kazuya Taguchi2, Yoshiyuki Yamaguchi2
1Department of Molecular Targeted Therapeutics, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
None:
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes organ damage and negatively affects a patient's quality of life (QoL). Despite the recent remarkable progress in treatment, patients continue to experience a substantial disease burden. In SLE, which is more common in young people, this casts a sizable shadow over patients' social activities. Treatment goals are to control disease activity, minimise treatment-related adverse events, avoid organ damage, and optimise health-related QoL. However, optimising QoL remains challenging, as many unresolved issues remain, including subjective symptoms, which are difficult for physicians to perceive. As such, physicians must work to understand this burden from the patient's perspective and pursue improved patient QoL. In this review, we discuss issues associated with disease burden and health-related QoL faced by patients with SLE in their daily lives, along with available treatments and management practices that can be implemented to optimise them. To enable SLE patients to live a normal life, we must transform current SLE care to move beyond symptom control to drive clinical remission, assessing and addressing the disease burden patients face in daily life.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease I: Introduction
Nephrotic Syndrome I : Introduction

